Krka

Lek, the Ljubljana-based pharmaceutical company, has been chosen Slovenia's best employer for the fourth year running. Before that, its Novo Mesto counterpart Krka won the title eight times.

The Slovenian pharma group Krka generated record high sales revenue and profit last year. Revenue was up by 10% to €1.7 billion and net profit rose by 17% to €361 million, according to unaudited results released by the company on 26 January.

Krka saw sales going up in most of its key markets and across all product and service segments.

The SBI TOP benchmark index on the Ljubljana Stock Exchange lost nearly 16% in 2022, after having risen by almost 40% the year before, show figures released by the stock exchange operator Ljubljanska Borza.

All the big-cap stocks were down with drug maker Krka losing nearly a fifth of its value in a year, NLB bank down by 18%, and energy group Petrol losing 21%.

Novo Mesto/Otočec – Pharmaceutical group Krka posted a net profit of EUR 177.4 million for the first half of the year, up 11% on the back of sales that reached EUR 808.6 million, up 1% over the same period last year, CEO Jože Colarič said at the company’s annual general meeting in Otočec on Thursday.

Novo Mesto – The Novo Mesto-based pharmaceutical group Krka generated EUR 1.53 billion in revenue last year, up 3% compared to 2019, while net profit has been estimated at EUR 286.6 million, up 17% year-on-year, show the unaudited preliminary results released on Thursday.

Gažić noted that the considerable interest from investors despite worrying trends on the capital markets made the event satisfying.